ReviewTrends in molecular medicine2020
TLR2 as a Therapeutic Target in Bacterial Infection.
Review in Trends in molecular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 56 citations in OpenAlex.
- Toward a Vaccine Against Multidrug-Resistant Elizabethkingia anophelis: Comprehensive Immunoinformatics-Based Design of a Multi-Epitope Vaccine and mRNA Construct.Probiotics and antimicrobial proteins · 2026Article
- Antiviral innate immunity and adaptive immune responses against monkeypox and viral immune evasion.World journal of virology · 2026Review
- Nisin bacteriocin blocks T. denticola-triggered MMP2 activation and pathogen internalization via TLR2.Scientific reports · 2026Article
- Autoimmune Diseases and Mycobacterial Infection.Diseases (Basel, Switzerland) · 2026Review
- Commensal Peptoniphilus harei induce activation of monocytes via TLR2/CD14 signalling in whole blood.Medical microbiology and immunology · 2025Article
- Akkermansia muciniphila: a microbial guardian against oxidative stress-gut microbiota crosstalk and clinical prospects.Journal of translational medicine · 2025Review
- Langerhans Cell Modulation in Atopic Dermatitis Is TLR2/SOCS1-Dependent and JAK Inhibitor-Sensitive.Allergy · 2025Article
- Multifaceted Role of Microbiota-Derived Indole-3-Acetic Acid in Human Diseases and Its Potential Clinical Application.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Review
- FSL-1 Pre-Administration Protects Radiation-Induced Hematopoietic Organs Through the Modulation of the TLR Signaling Pathway.International journal of molecular sciences · 2025Article
- Insights into the roles of macrophages in Klebsiella pneumoniae infections: a comprehensive review.Cellular & molecular biology letters · 2025Review
- Article
- Fucosylated Glycosaminoglycan Oligosaccharide HS14, Derived from Sea Cucumbers, Is a Novel Inhibitor of Platelet Toll-like Receptor 2.Marine drugs · 2025Article
- Biomarker expression level changes within rectal gut-associated lymphoid tissues in spinal cord-injured rats.ImmunoHorizons · 2025Article
- Human colon stem cells are the predominant epithelial responders to bacterial antigens.Frontiers in immunology · 2025Article
- Sparstolonin B potentiates the antitumor activity of nanovesicle-loaded drugs by suppressing the phagocytosis of macrophages in vivo.Journal of nanobiotechnology · 2024Article
- Genomic Insights into Host Susceptibility to Periprosthetic Joint Infections: A Comprehensive Literature Review.Microorganisms · 2024Review
- Mono-Palmitoyl-N-Alkylurea Ligands as Specific Activators of Human Toll-Like Receptor 2/6 Heterodimer.Chembiochem : a European journal of chemical biology · 2024Article
- Article
- TLR2 regulatesVirulence · 2024Article
- Immunostimulation Signaling via Toll-like Receptor 2 Activation: A Molecular Mechanism ofNutrients · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Toll-like receptor (TLR) 2 recognizes and responds to threats early in bacterial infections and can influence the downstream immune response to the host's benefit or detriment. Therapeutic modulation of TLR2 signaling represents an underutilized opportunity to moderate the immune response to infection to promote an improved outcome for the host.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.